AN OPEN-LABEL, MULTICOHORT, PHASE IISTUDY OF MPDL3280A IN ADVANCED SOLIDTUMORS

Protocol: 
AAAP4558
Phase: 
II

AN OPEN-LABEL, MULTICOHORT, PHASE IISTUDY OF MPDL3280A IN ADVANCED SOLIDTUMORS

The purpose of this study is to find out what effects, good or bad, MPDL3280A has on advanced solid tumors. This is a phase II study to test the effectiveness of the drug as a potential treatment option for people with cancer. MPDL3280A is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the PD-L1 pathway. The PD-L1 pathway is involved in regulating the body’s natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD-L1 pathway, MPDL3280A may help your immune system stop or reverse the growth of tumors.

Are you Eligible? (Inclusion Criteria)

1.Signed Informed Consent Form
2.Ability to comply with protocol
3.Male or female, 18 years of age or older.
4.ECOG Performance Status of 0 or 1
5.Adequate hematologic and end organ function, defined by the following
laboratory results obtained within 14 days prior to the first study treatment
(Cycle 1, Day 1)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States